Irvine, California– December 6, 2021 – Genomic Testing Cooperative, LCA (GTC) announced the presentation of four innovative studies at the annual American Society of Hematology
CHICAGO – With the publication of a paper validating two artificial intelligence-based algorithms for assisting pathologists in molecular profiling of patients, the Genomic Testing Cooperative
IRVINE, CA- Genomic Testing Cooperative, LCA (GTC) announced that its innovative artificial intelligence (AI) algorithms are now formally implemented in daily use to aid pathologists in the
SAN FRANCISCO (PRWEB) JUNE 14, 2022. HALO Diagnostics, a precision diagnostics leader, has joined forces with the Genomic Testing Cooperative (GTC) to offer innovative, personalized testing to its physician network and 1M+ patients served. This solution combines HALO Diagnostics’ clinical ensemble and image-guided therapies with GTC’s genomic profiling of a patient’s DNA / RNA using liquid biopsy and tissue samples. Together, the companies will help patients on every step of their unique healthcare journey – from detection and diagnosis to prognosis and treatment.
Irvine, California– June 1, 2022 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO)
IRVINE, California, May 25, 2022 – Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as
IRVINE, California, March 2, 2022, Genomic Testing Cooperative, LCA (GTC) announced today that their hematology molecular profiling is expanded to cover analysis of the UBA1
Irvine, California– December 1, 2021 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the annual American Society of Hematology (ASH)
Irvine, CA – June 30th – Genomic Testing Cooperative, a first-in-class diagnostic company based on a cooperative business model (Co-Op) using the most recent advances
Irvine, California– June 23, 2021 – Genomic Testing Cooperative, LCA (GTC) announced that the New York State Clinical Evaluation Program (CLEP) has completed their evaluation
